## Declan McLoughlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9371346/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Online news media reporting of ketamine as a treatment for depression from 2000 to 2017. Irish Journal of Psychological Medicine, 2023, 40, 607-615.	1.0	5
2	Dublin hospital workers' mental health during the peak of Ireland's COVID-19 pandemic. Irish Journal of Medical Science, 2023, 192, 1293-1302.	1.5	2
3	Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness. Biological Psychiatry, 2022, 91, 531-539.	1.3	11
4	Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation. Molecular Psychiatry, 2022, 27, 1120-1135.	7.9	27
5	Nursing home staff mental health during the Covidâ€19 pandemic in the Republic of Ireland. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	32
6	Telomere length in patients with anorexia nervosa. Psychiatry Research Communications, 2022, 2, 100022.	1.0	0
7	Twelve-month outcomes for remitters following electroconvulsive therapy for depression. Journal of Clinical Psychiatry, 2022, 83, .	2.2	Ο
8	Peripheral blood inflammatory markers in depression: Response to electroconvulsive therapy and relationship with cognitive performance. Psychiatry Research, 2022, 315, 114725.	3.3	7
9	Speed of electroconvulsive therapy for depression: Effects of electrode placement. Acta Psychiatrica Scandinavica, 2021, 143, 444-452.	4.5	6
10	Electroconvulsive therapy for depression: 80 years of progress. British Journal of Psychiatry, 2021, 219, 594-597.	2.8	30
11	Relapse following bitemporal and highâ€dose right unilateral electroconvulsive therapy for major depression. Acta Psychiatrica Scandinavica, 2021, 144, 218-229.	4.5	8
12	PBMC telomerase activity in depression and the response to electroconvulsive therapy. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1297-1307.	3.2	1
13	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. International Journal of Bipolar Disorders, 2021, 9, 26.	2.2	6
14	Decision-making Capacity for Treatment After Electroconvulsive Therapy for Depression. Journal of ECT, 2021, Publish Ahead of Print, .	0.6	2
15	Usefulness of Hamilton rating scale for depression subset scales and full versions for electroconvulsive therapy. PLoS ONE, 2021, 16, e0259861.	2.5	7
16	Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy. Brain, Behavior, and Immunity, 2020, 83, 153-162.	4.1	33
17	Telomere length in depression and association with therapeutic response to electroconvulsive therapy and cognitive side-effects. Psychological Medicine, 2020, 50, 2096-2106.	4.5	9
18	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	3.2	22

#	Article	IF	CITATIONS
19	Blood plasma B vitamins in depression and the therapeutic response to electroconvulsive therapy. Brain, Behavior, & Immunity - Health, 2020, 4, 100063.	2.5	12
20	Vascular endothelial growth factor and pigment epithelial-derived factor in the peripheral response to ketamine. Journal of Affective Disorders, 2020, 273, 380-383.	4.1	14
21	Physician, heal thyself: a cross-sectional survey of doctors' personal prescribing habits. Journal of Medical Ethics, 2020, 46, 231-235.	1.8	4
22	Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial). HRB Open Research, 2020, 3, 90.	0.6	4
23	Alcohol Use Disorder and Comorbid Depression: A Randomized Controlled Trial Investigating the Effectiveness of Supportive Text Messages in Aiding Recovery. Alcohol and Alcoholism, 2019, 54, 551-558.	1.6	32
24	Should we stop using electroconvulsive therapy?. BMJ: British Medical Journal, 2019, 364, k5233.	2.3	31
25	Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy. Journal of ECT, 2019, 35, 115-121.	0.6	13
26	Peroxisome proliferator-activated receptor gamma co-activator-1 alpha in depression and the response to electroconvulsive therapy. Psychological Medicine, 2019, 49, 1859-1868.	4.5	16
27	Peripheral blood GILZ mRNA levels in depression and following electroconvulsive therapy. Psychoneuroendocrinology, 2019, 101, 304-310.	2.7	5
28	Peripheral blood E2F1 mRNA in depression and following electroconvulsive therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 380-385.	4.8	5
29	Ketamine and depression: A special kase for kynurenic acid?. Brain, Behavior, and Immunity, 2019, 75, 10-11.	4.1	0
30	Involuntary and voluntary electroconvulsive therapy: A case-control study. Brain Stimulation, 2018, 11, 860-862.	1.6	20
31	Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy. Journal of Psychiatric Research, 2018, 100, 24-32.	3.1	34
32	Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes. Psychoneuroendocrinology, 2018, 95, 8-17.	2.7	69
33	BDNF plasma levels and genotype in depression and the response to electroconvulsive therapy. Brain Stimulation, 2018, 11, 1123-1131.	1.6	38
34	Vascular endothelial growth factor plasma levels in depression and following electroconvulsive therapy. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 839-848.	3.2	15
35	Peripheral blood SIRT1 mRNA levels in depression and treatment with electroconvulsive therapy. European Neuropsychopharmacology, 2018, 28, 1015-1023.	0.7	17
36	I know not â€~seems'. Australian and New Zealand Journal of Psychiatry, 2018, 52, 709-710.	2.3	2

#	Article	IF	CITATIONS
37	Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders. Neuropharmacology, 2017, 112, 307-323.	4.1	105
38	Electroconvulsive stimulation transiently enhances the permeability of the rat blood-brain barrier and induces astrocytic changes. Brain Research Bulletin, 2017, 128, 92-97.	3.0	11
39	Anodal transcranial direct current stimulation of the left dorsolateral prefrontal cortex enhances emotion recognition in depressed patients and controls. Journal of Clinical and Experimental Neuropsychology, 2017, 39, 384-395.	1.3	35
40	Response to Kellner and Farber: Addressing Crossover of High-Dose Right Unilateral ECT to Bitemporal ECT. American Journal of Psychiatry, 2016, 173, 731-732.	7.2	7
41	Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial). Pilot and Feasibility Studies, 2016, 2, 38.	1.2	3
42	Task shifting—perception of stake holders about adequacy of training and supervision for community mental health workers in Ghana. Health Policy and Planning, 2016, 31, 645-655.	2.7	17
43	Bitemporal Versus High-Dose Unilateral Twice-Weekly Electroconvulsive Therapy for Depression (EFFECT-Dep): A Pragmatic, Randomized, Non-Inferiority Trial. American Journal of Psychiatry, 2016, 173, 408-417.	7.2	132
44	Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. Journal of Affective Disorders, 2015, 186, 306-311.	4.1	90
45	SEQUenCE: a service user-centred quality of care instrument for mental health services. International Journal for Quality in Health Care, 2015, 27, 284-290.	1.8	8
46	Construction and updating of a public events questionnaire for repeated measures longitudinal studies. Frontiers in Psychology, 2014, 5, 230.	2.1	0
47	Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression. International Journal of Neuropsychopharmacology, 2014, 17, 1477-1486.	2.1	19
48	Expression of glucocorticoid inducible genes is associated with reductions in cornu ammonis and dentate gyrus volumes in patients with major depressive disorder. Development and Psychopathology, 2014, 26, 1209-1217.	2.3	19
49	Acute phase plasma proteins are altered by electroconvulsive stimulation. Journal of Psychopharmacology, 2014, 28, 1125-1134.	4.0	5
50	Epigenetics and depression: return of the repressed. Journal of Affective Disorders, 2014, 155, 1-12.	4.1	107
51	The persisting effects of electroconvulsive stimulation on the hippocampal proteome. Brain Research, 2014, 1593, 106-116.	2.2	1
52	Electroconvulsive stimulation alters levels of BDNF-associated microRNAs. Neuroscience Letters, 2013, 549, 125-129.	2.1	46
53	Relapse Following Successful Electroconvulsive Therapy for Major Depression: A Meta-Analysis. Neuropsychopharmacology, 2013, 38, 2467-2474.	5.4	204
54	Mauling of the "Celtic Tiger― Clinical characteristics and outcome of first-episode depression secondary to the economic recession in Ireland. Journal of Affective Disorders, 2013, 151, 455-460.	4.1	11

#	Article	IF	CITATIONS
55	Measuring Retrograde Autobiographical Amnesia Following Electroconvulsive Therapy. Journal of ECT, 2013, 29, 127-133.	0.6	79
56	Measuring consistency of autobiographical memory recall in depression. Psychiatry Research, 2012, 197, 41-48.	3.3	45
57	A comparison of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 147-152.	4.8	19
58	Systematic review and meta-analysis of bifrontal electroconvulsive therapy versus bilateral and unilateral electroconvulsive therapy in depression. World Journal of Biological Psychiatry, 2012, 13, 248-258.	2.6	81
59	Unilateral brief-pulse electroconvulsive therapy and cognition: Effects of electrode placement, stimulus dosage and time. Journal of Psychiatric Research, 2011, 45, 770-780.	3.1	77
60	Dementia in Clinical Practice (Frontiers of Neurology and Neuroscience, Vol. 24) Editors: Panteleimon Giannakopoulos and Patrick R. Hof Basel, Switzerland: Karger, 2009, â,¬141.50 Hardback, 184 pp ISBN 978-3-8055-9015-0. International Psychogeriatrics, 2010, 22, 340-340.	1.0	0
61	Expression of the Neuronal Adaptor Protein X11α Protects Against Memory Dysfunction in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 31-36.	2.6	10
62	Objective Cognitive Performance Associated with Electroconvulsive Therapy for Depression: A Systematic Review and Meta-Analysis. Biological Psychiatry, 2010, 68, 568-577.	1.3	550
63	Review: high frequency repetitive transcranial magnetic stimulation improves symptoms of major depression. Evidence-Based Mental Health, 2009, 12, 80-81.	4.5	2
64	Methohexitone, propofol and etomidate in electroconvulsive therapy for depression: A naturalistic comparison study. Journal of Affective Disorders, 2009, 113, 165-171.	4.1	34
65	Phosphorylation of thr668 in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). Journal of Neurochemistry, 2009, 76, 316-320.	3.9	113
66	Electroconvulsive therapy, capacity and the law in Ireland. Irish Journal of Psychological Medicine, 2009, 26, 3-5.	1.0	4
67	The FE65 proteins and Alzheimer's disease. Journal of Neuroscience Research, 2008, 86, 744-754.	2.9	130
68	Deregulation of PKN1 activity disrupts neurofilament organisation and axonal transport. FEBS Letters, 2008, 582, 2303-2308.	2.8	36
69	Capacity, consent and electroconvulsive therapy: A qualitative and cross-sectional study. Journal of Mental Health, 2008, 17, 315-325.	1.9	3
70	Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Human Molecular Genetics, 2007, 16, 2720-2728.	2.9	365
71	Review: repetitive transcranial magnetic stimulation is of unknown effectiveness in people with depression. Evidence-Based Mental Health, 2003, 6, 118-118.	4.5	1
72	THE XI1 AND FE65 PROTEINS IN ALZHEIMER'S DISEASE. Biochemical Society Transactions, 2000, 28, A37-A37.	3.4	0

#	Article	IF	CITATIONS
73	Structural and functional changes in skeletal muscle in anorexia nervosa. Acta Neuropathologica, 1998, 95, 632-540.	7.7	95
74	Mapping of the human and murine X11-like genes (APBA2 and Apba2 ), the murine Fe65 gene ( Apbb1 ), and the human Fe65-like gene (APBB2): genes encoding phosphotyrosine-binding domain proteins that interact with the Alzheimer's disease amyloid precursor protein. Mammalian Genome, 1998, 9, 473-475.	2.2	26
75	Cyclin D2 Interacts with cdkâ€5 and Modulates Cellular cdkâ€5/p35 Activity. Journal of Neurochemistry, 1998, 70, 335-340.	3.9	33
76	The relationship between extrapyramidal signs and cognitive function in patients with moderate to severe Alzheimer's disease. International Journal of Geriatric Psychiatry, 1995, 10, 395-399.	2.7	11
77	Natural Born Killers. Psychiatric Bulletin, 1995, 19, 499-500.	0.3	0
78	Alzheimer's disease: Recent advances in molecular pathology and genetics. International Journal of Geriatric Psychiatry, 1994, 9, 431-444.	2.7	9
79	The Fourth International Conference on Alzheimer's disease and related disorders, 29 July-3 August, 1994, Minneapolis, Minnesota, USA. International Journal of Geriatric Psychiatry, 1994, 9, 1003-1004.	2.7	1
80	Psychotherapy training in Turkey. Psychiatric Bulletin, 1994, 18, 650-651.	0.3	0
81	Bipolar Disorder and Cerebral Sarcoidosis. British Journal of Psychiatry, 1991, 158, 410-413.	2.8	9
82	Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial). HRB Open Research, 0, 3, 90.	0.6	2